The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Navigating this part of the market can be tricky, which is why we built StockStory to help you separate the winners from the laggards. Keeping that in mind, here are three Russell 2000 stocks to avoid and better alternatives to consider.
Health Catalyst (HCAT)
Market Cap: $168.3 million
Built on its "Health Catalyst Flywheel" methodology that emphasizes measurable outcomes, Health Catalyst (NASDAQ: HCAT) provides data and analytics technology and services that help healthcare organizations manage their data and drive measurable clinical, financial, and operational improvements.
Why Do We Pass on HCAT?
- Annual revenue growth of 4.4% over the last two years was well below our standards for the software sector
- Extended payback periods on sales investments suggest the company’s platform isn’t resonating enough to drive efficient sales conversions
- Cash-burning history makes us doubt the long-term viability of its business model
At $2.39 per share, Health Catalyst trades at 0.5x forward price-to-sales. If you’re considering HCAT for your portfolio, see our FREE research report to learn more.
Calavo (CVGW)
Market Cap: $383.1 million
A trailblazer in the avocado industry, Calavo Growers (NASDAQ: CVGW) is a pioneering California-based provider of high-quality avocados and other fresh food products.
Why Should You Sell CVGW?
- Sales tumbled by 17.2% annually over the last three years, showing consumer trends are working against its favor
- Modest revenue base of $693.7 million gives it less fixed cost leverage and fewer distribution channels than larger companies
- Easily substituted products (and therefore stiff competition) result in an inferior gross margin of 10.1% that must be offset through higher volumes
Calavo’s stock price of $21.16 implies a valuation ratio of 12.2x forward P/E. Check out our free in-depth research report to learn more about why CVGW doesn’t pass our bar.
Collegium Pharmaceutical (COLL)
Market Cap: $1.46 billion
Pioneering abuse-deterrent technology in a field plagued by addiction concerns, Collegium Pharmaceutical (NASDAQ: COLL) develops and markets specialty medications for treating moderate to severe pain, including abuse-deterrent opioid formulations.
Why Do We Think Twice About COLL?
- Subscale operations are evident in its revenue base of $757.1 million, meaning it has fewer distribution channels than its larger rivals
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
Collegium Pharmaceutical is trading at $44.48 per share, or 6x forward P/E. To fully understand why you should be careful with COLL, check out our full research report (it’s free for active Edge members).
Stocks We Like More
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
